{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 22,
  "pageCount": 41,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a two-column layout to contrast immunogenicity and safety outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/22",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.53,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Safety profile supported Phase 3 progression with medium dose",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "529bc255-c7ff-4acc-a811-a210ef04b13b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Highly immunogenic after single vaccination",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b24c86e6-deb9-4793-983c-74d4c76a1f14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Safety: No safety concerns identified... Excellent local tolerability... Systemic adverse events included short-term fever... No vaccine related Serious Adverse Events",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66bc5eac-9972-4ad3-83f4-2c609dfa241a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "list",
      "text": "Immunogenicity: 100% Seroconversion Rate achieved at Day 14... sustaining, high-titer, neutralizing antibodies... No anamnesic response... No vaccine-strain viremia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fc9326c-36fb-4627-be79-64d524b7d98f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.06,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "1 Wressnigg et al. 2020; Lancet Infect Dis 20:1193-1203.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f63721a3-36bf-41db-b08e-3509aafcf0ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.06,
        "y": 0.11
      },
      "kind": "title",
      "text": "Clinical Trial VLA1553-101 Published in Lancet ID",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49e64723-9a75-4a20-892d-d75fa848ed2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "VLA1553: Clinical Data in Phase 1 in 120 Subjects",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dedf5972-c10c-4db3-b40d-7b322e62b473",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "ae44eb44-12c5-4499-8a52-370bb9578706",
      "evidence": "list/bullet: Safety: No safety concerns identified... Excellent local tolerability... Systemic adverse events included short-term fever... No vaccine related Serious Adverse Events",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}